Background

Factor XIII (FXIII) deficiency, also known as fibrin-stabilizing factor deficiency, is a rare and inherited bleeding disorder characterized by inadequate or deficient levels of Factor XIII in the blood. Factor XIII is a crucial clotting factor that plays an important role in stabilizing blood clots by cross-linking fibrin molecules, which are the building blocks of a stable clot. Cross-linking strengthens the clot’s structure and prevents premature degradation, ensuring proper wound healing and protection against excessive bleeding.

The disorder is caused by mutations in the F13A1 or F13B genes, which encode the A and B subunits of Factor XIII, respectively. Factor XIII deficiency is classified into two main types: congenital (inherited) and acquired. The congenital form is typically diagnosed in childhood and is passed down through families in an autosomal recessive pattern. Acquired Factor XIII deficiency may occur due to various factors, such as liver disease, certain medications, or autoimmune disorders. 

Individuals with Factor XIII deficiency are prone to spontaneous and delayed bleeding after injuries or surgical procedures. Common symptoms include prolonged bleeding from wounds, easy bruising, bleeding into joints and muscles, and excessive bleeding during menstruation. Severe bleeding can be life-threatening and may lead to serious complications. The diagnosis is confirmed through specific laboratory tests that assess the activity levels of Factor XIII in the blood. Treatment often involves replacement therapy with purified Factor XIII concentrates to prevent bleeding episodes and promote clot stability.  

Epidemiology

Factor XIII deficiency is an infrequent bleeding disorder that can be either inherited or acquired.  

Inherited Factor XIII Deficiency: 

• Prevalence: Inherited Factor XIII deficiency is estimated to have a worldwide incidence of around one per 1-3 million people. 
• Inheritance: It is an autosomal recessive disorder, i.e., both parents must carry a mutated gene for the condition to be passed on to their child. 
• Onset: Symptoms of inherited Factor XIII deficiency typically appear soon after birth, and the diagnosis is often made during infancy. 
• Common Signs: Common signs of the inherited form include umbilical cord bleeding (in up to 80% of patients), intracranial hemorrhage (in 25-30% of patients), soft tissue bleeding, bruising, hemarthroses (in 20% of patients), and recurrent spontaneous abortions. 
• Severity: The severity of the symptoms can vary, ranging from life-threatening intracranial hemorrhage to milder forms like skin bleeding. Heterozygous carriers may experience bleeding tendencies upon provocation, such as traumatic injury or invasive procedures. 

Acquired Factor XIII Deficiency: 

• Prevalence: The prevalence of acquired Factor XIII deficiency is not specifically mentioned in the provided information, but it is generally less common than the inherited form. 
• Onset: Acquired Factor XIII deficiency becomes apparent later in life. 
• Causes: Acquired Factor XIII deficiency is linked to chronic conditions like hepatic failure, inflammatory bowel disease, and myeloid leukemia. 

Anatomy

Pathophysiology

Factor XIII deficiency is an infrequent bleeding disorder characterized by a deficiency or dysfunction of Factor XIII, also known as a fibrin-stabilizing factor. Factor XIII is a critical component of the coagulation cascade, which is responsible for the formation and stabilization of blood clots. The pathophysiology of Factor XIII deficiency revolves around the impaired cross-linking of fibrin molecules, leading to weak and unstable blood clots. 

When there is a vascular injury or tissue damage, the initial stages of the coagulation cascade are activated, resulting in the formation of a fibrin clot. Fibrinogen, a soluble plasma protein, is converted into fibrin through thrombin. Fibrin molecules then form a loose network, which acts as the initial scaffold for the clot. However, this initial fibrin clot is fragile and easily degraded, making it insufficient to stop bleeding effectively. 

Factor XIII plays a key role in the next step of the coagulation process. It acts as a transglutaminase enzyme, catalyzing the formation of covalent bonds between adjoining fibrin molecules. This cross-linking process, or fibrin polymerization, strengthens the fibrin network, transforming the fragile fibrin clot into a stable and durable structure. 

In individuals with Factor XIII deficiency, this cross-linking process is impaired due to either insufficient levels or dysfunctional forms of Factor XIII. As a result, the fibrin clot remains weak and unstable, making it more susceptible to premature degradation. This leads to prolonged bleeding and delayed wound healing in affected individuals. Factor XIII deficiency can manifest as mild, moderate, or severe depending on the level of functional Factor XIII present. 

Factor XIII deficiency can be inherited in an autosomal recessive pattern caused by the mutations in the F13A1 or F13B genes, which encode the A and B subunits of Factor XIII, respectively. It can also be acquired in rare cases due to conditions that interfere with Factor XIII production or function, such as liver disease or autoimmune disorders. 

Etiology

Factor XIII deficiency, or fibrin-stabilizing factor deficiency, can have both congenital and acquired etiologies.  

Congenital Factor XIII Deficiency: Congenital Factor XIII deficiency is the most common form inherited in an autosomal recessive pattern, meaning both parents should have to carry a mutated gene for the disorder to be passed on to their child. The condition is caused by mutations in the genes that encode the A and B subunits of Factor XIII, known as F13A1 and F13B, respectively. These genetic mutations lead to reduced or dysfunctional Factor XIII activity, resulting in the deficiency of this critical clotting factor in the affected individual’s blood. The severity of the deficiency can vary depending on the specific mutations and the residual activity of Factor XIII. 

Acquired Factor XIII Deficiency: Acquired Factor XIII deficiency is much rarer than the congenital form and occurs due to factors that interfere with the production or function of Factor XIII. Some of the potential causes of acquired Factor XIII deficiency include: 

• Liver disease: Liver dysfunction can reduce the production of clotting factors, including Factor XIII, leading to a deficiency. 
• Autoimmune disorders: Certain autoimmune conditions can produce antibodies against Factor XIII, rendering it less effective or leading to its destruction in the bloodstream. 
• Severe infections: Infections, particularly severe bacterial or viral infections, can temporarily reduce Factor XIII levels. 
• Some medications: Certain medications, such as antiepileptic drugs and isoniazid (used to treat tuberculosis), can interfere with Factor XIII activity and cause acquired deficiency. 
• Vitamin K deficiency: Vitamin K, a crucial nutrient for clotting factor synthesis, can impair Factor XIII production. 

Genetics

Prognostic Factors

The prognosis of Factor XIII deficiency, a rare bleeding disorder, can vary depending on several factors. Proper management and timely treatment significantly influence the outlook of affected individuals.  

• Severity of Deficiency: The severity of Factor XIII deficiency is determined by the residual activity of Factor XIII in the blood. Individuals with more severe deficiencies are at higher risk of experiencing spontaneous bleeding episodes, delayed wound healing, and more significant bleeding complications. Those with milder deficiencies may have fewer bleeding issues but still require vigilant management. 
• Age at Diagnosis and Treatment Initiation: Early diagnosis and treatment initiation are crucial in improving the prognosis. Individuals diagnosed and treated early in life may experience fewer complications and enjoy a better quality of life. Delayed diagnosis and treatment can result in more significant bleeding events and long-term complications. 
• Presence of Bleeding Episodes: The frequency and severity of bleeding episodes can impact the prognosis. Individuals who experience frequent and severe bleeding events may have a more challenging prognosis than those with fewer or milder bleeding episodes. 
• Adequacy of Treatment: Proper management and adherence to treatment are essential for favorable outcomes. Replacement therapy with purified Factor XIII concentrates is the primary treatment for Factor XIII deficiency. Regular infusion of Factor XIII concentrates helps prevent bleeding episodes and improve clot stability. Adherence to the prescribed treatment plan and regular follow-up with healthcare professionals specialized in bleeding disorders is crucial for optimal outcomes. 
• Complications: Factor XIII deficiency can lead to complications such as joint and muscle bleeding, intracranial hemorrhage, and delayed wound healing. These complications can impact affected individuals’ long-term prognosis and quality of life. 
• Associated Conditions: Some individuals with Factor XIII deficiency may have additional health conditions or comorbidities that can influence the overall prognosis. For example, individuals with liver disease or autoimmune disorders may have more complex management requirements. 
• Lifestyle and Environmental Factors: Lifestyle choices and environmental factors can also influence the prognosis of Factor XIII deficiency. Engaging in activities that increase the risk of injury or trauma may exacerbate bleeding complications. 

Clinical History

Age Group:

Factor XIII deficiency can present at any age, but the age of presentation might vary based on severity of the deficiency. In severe cases, symptoms may become evident in the neonatal period, with umbilical cord bleeding or intracranial hemorrhage being potential complications. In moderate or milder cases, symptoms may not manifest until later in childhood or adolescence, as individuals become more active and experience injuries or surgeries. 

Physical Examination

The physical examination of a person suspected to have Factor XIII deficiency is essential in the diagnostic process. An in-depth examination and a detailed medical history can provide valuable clues to support or rule out the diagnosis of this rare bleeding disorder.  

• Bruising and Petechiae: The presence of bruising (ecchymosis) and petechiae (tiny red or purple spots) on the skin may be observed, particularly in areas prone to minor trauma, such as the arms and legs. These findings can indicate a bleeding tendency and warrant further investigation. 
• Wound Healing: Delayed wound healing may be noticeable, as individuals with Factor XIII deficiency may have difficulty forming stable blood clots, leading to prolonged bleeding from cuts or wounds. 
• Joint Swelling and Pain: Bleeding into joints (hemarthrosis) is a common complication in individuals with bleeding disorders. A physical examination may reveal signs of joint swelling, warmth, tenderness, and limited range of motion in affected joints. 
• Muscle Hematomas: Muscle hematomas (bleeding into muscles) can cause localized swelling, tenderness, and sometimes palpable masses in affected areas. 
• Ecchymoses in Unexpected Locations: Unusual or disproportionate bruising in uncommon areas, such as the trunk or abdomen, may indicate a bleeding disorder. 
• Bleeding from Mucous Membranes: Bleeding from mucous membranes, such as the gums or nosebleeds (epistaxis), may be observed, especially in more severe cases of Factor XIII deficiency. 
• Signs of Intracranial Bleeding: In severe cases, intracranial bleeding (bleeding inside the skull) may occur and can present with neurological symptoms such as headaches, altered mental status, seizures/focal neurological deficits. 

Age group

Associated comorbidity

There may not be specific associated comorbidities linked to Factor XIII deficiency, as it is primarily an inherited genetic disorder. However, certain conditions or activities that increase the risk of injury can exacerbate bleeding complications.

For example, individuals who engage in contact sports, have a history of trauma or participate in activities with a higher risk of bleeding may experience more frequent bleeding episodes. Additionally, individuals with other coagulation disorders or liver disease may have increased bleeding tendencies if they also have Factor XIII deficiency. 

Associated activity

Acuity of presentation

The acuity of presentation in Factor XIII deficiency can vary. In severe cases, the deficiency may present life-threatening bleeding episodes, such as intracranial hemorrhage or spontaneous bleeding into muscles or joints. These severe bleeding events often prompt immediate medical attention and investigation.

In milder cases, the initial presentation may involve less severe bleeding episodes, such as prolonged bleeding from cuts, delayed wound healing, or excessive bruising. In some cases, the diagnosis of Factor XIII deficiency may not be made until later in life if mild bleeding symptoms are attributed to other factors initially. 

Differential Diagnoses

The diagnosis of Factor XIII deficiency requires a comprehensive evaluation, as its symptoms can overlap with those of other bleeding disorders.  

• Hemophilia A and Hemophilia B: These are X-linked recessive bleeding disorders caused by deficiencies in clotting Factor VIII (hemophilia A)/Factor IX (hemophilia B). Both conditions can present with prolonged bleeding after injuries, joint bleeds, and spontaneous bleeding. However, unlike Factor XIII deficiency, they do not typically cause delayed wound healing or increased bleeding from mucous membranes. 
• von Willebrand Disease (vWD): vWD is the most common inherited bleeding disorder which is generally caused by deficiencies or abnormalities in von Willebrand factor (vWF). This protein is critical in platelet adhesion and stabilization of Factor VIII. vWD can present many bleeding symptoms, including easy bruising, mucous membrane bleeding, and prolonged bleeding from cuts and wounds. 
• Platelet Function Disorders: Platelet function disorders, such as Glanzmann thrombasthenia or Bernard-Soulier syndrome, are rare disorders characterized by defects in platelet function or numbers. These conditions can lead to bleeding tendencies similar to those seen in Factor XIII deficiency, including prolonged bleeding after injuries and mucous membrane bleeding. 
• Vitamin K Deficiency: It is essential for synthesizing multiple clotting factors, including Factors II, VII, IX, and X. Vitamin K deficiency can lead to coagulation factor deficiencies and result in bleeding tendencies. Unlike Factor XIII deficiency, vitamin K deficiency does not primarily affect clot stabilization. 
• Disseminated Intravascular Coagulation (DIC): DIC is a complex and life-threatening condition characterized by widespread activation of the clotting cascade, leading to excessive clotting and subsequent bleeding. While DIC and Factor XIII deficiency can present with bleeding symptoms, they have different underlying pathophysiology and require distinct treatment approaches. 
• Other Rare Clotting Factor Deficiencies: Numerous rare clotting factor deficiencies can manifest with bleeding symptoms. Examples include Factor II (prothrombin) deficiency, Factor V deficiency, and Factor X deficiency. 

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

Factor XIII deficiency’s treatment paradigm revolves around replacing the deficient or dysfunctional Factor XIII. The mainstay of treatment is the infusion of purified Factor XIII concentrates derived from human plasma or produced recombinantly. These concentrates contain both the A and B subunits of Factor XIII and can effectively replace the missing or insufficient clotting factor.

The dosing and frequency of Factor XIII infusions depend on the individual’s severity of deficiency and bleeding tendencies. Prophylactic treatment with regular infusions may be recommended for individuals with severe deficiencies or frequent bleeding episodes. In contrast, those with milder deficiencies may receive on-demand treatment when bleeding occurs. Additionally, patients should be educated about recognizing early signs of bleeding and have access to treatment facilities for prompt management. 

In cases where Factor XIII concentrates are unavailable or unsuitable, fresh frozen plasma (FFP) can be used as an alternative treatment option. However, FFP may not provide consistent and predictable Factor XIII levels, and the volume required for effective treatment can be substantial. Genetic counseling is also an essential component of the treatment paradigm for Factor XIII deficiency, especially in the congenital form, to educate affected individuals and their families about the genetic inheritance pattern and potential risks for future generations.

With appropriate and timely treatment, individuals with Factor XIII deficiency can effectively prevent bleeding episodes, minimize complications, and lead a relatively everyday life. Regular follow-up and monitoring by a hematologist or a healthcare professional specialized in bleeding disorders are essential to ensure optimal treatment outcomes and address any emerging issues promptly. 

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

use-of-the-non-pharmacological-therapy-for-modifying-the-environment

Modifying the environment plays an essential role in managing individuals with Factor XIII deficiency, particularly in preventing injuries and bleeding episodes.  

• Injury Prevention: Minimizing the risk of injuries can help prevent bleeding episodes. Individuals with Factor XIII deficiency should be encouraged to avoid activities with a high risk of trauma or injury, such as contact sports or activities that may lead to falls or collisions. 
• Safety Measures: Implementing safety measures in the home and workplace can reduce the likelihood of accidents. Using non-slip mats, removing sharp objects, and ensuring proper lighting can create a safer environment. 
• Protective Gear: For individuals who wish to participate in physical activities or sports, wearing appropriate protective gear such as helmets, knee pads, and elbow pads can offer an extra layer of protection against injuries. 
• Regular Exercise: Regular, low-impact exercise can help maintain joint health and overall fitness without significantly increasing the risk of injuries. Physical activity should be discussed with a healthcare professional to ensure it is safe and also appropriate. 
• Dental Care: Individuals with Factor XIII deficiency should practice good oral hygiene to diminish the risk of gum bleeding and oral injuries. Frequent dental check-ups are important for maintaining oral health. 
• Avoiding Certain Medications: Medications like nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and anticoagulants, can increase the risk of bleeding. Individuals with Factor XIII deficiency should avoid these medications unless prescribed by a healthcare professional aware of their bleeding disorder. 

• Travel Precautions: Individuals with Factor XIII deficiency should be prepared with adequate supplies of Factor XIII concentrates or other prescribed treatments. They should also carry medical identification cards or bracelets to inform healthcare providers about their emergency conditions. 
• Education and Awareness: Increasing awareness about Factor XIII deficiency among family members, friends, teachers, and coworkers can create a supportive environment for affected individuals. It can also help others understand the importance of safety precautions and prompt action during bleeding episodes. 

Use of Recombinant factor XIII A subunit for treating Factor XIII Deficiency

Recombinant Factor XIII A subunit (rFXIII-A) is a synthetic form of the missing factor XIII, and it is used as a replacement therapy for patients with Factor XIII Deficiency. It helps to restore the missing clotting factor and improve the stability of blood clots, reducing the risk of bleeding episodes. 

• Administration: Recombinant Factor XIII A subunit is usually administered by intravenous (IV) infusion. The dosage and frequency of infusions depend on the severity of the deficiency and the individual patient’s needs. 
• Prophylaxis: In some cases, especially for patients with severe Factor XIII Deficiency, regular prophylactic treatment with rFXIII-A may be recommended. This means administering the factor on a scheduled basis to prevent bleeding episodes. 
• On-demand treatment: For patients with milder forms of Factor XIII Deficiency or those who experience bleeding episodes less frequently, rFXIII-A may be given on-demand when bleeding occurs. 
• Individualized treatment: The treatment plan is often individualized based on the patient’s medical history, bleeding pattern, and response to therapy. 
• Monitoring: Regular monitoring of Factor XIII levels and bleeding episodes is essential to assess the effectiveness of the therapy and make adjustments as necessary. 
• Safety and side effects: As with any medication, rFXIII-A may have potential side effects or adverse reactions. Common side effects may include headache, fever, and injection site reactions. Serious allergic reactions are possible but rare. 
• Pregnancy and lactation: Patients with Factor XIII Deficiency who are pregnant condition or breastfeeding should discuss treatment options and potential risks with their healthcare providers. 

Use of Plasma-derived factor XIII concentrate for treating Factor XIII Deficiency

Plasma-derived Factor XIII concentrate is another treatment option for patients with Factor XIII Deficiency. Like Recombinant Factor XIII A subunit (rFXIII-A), plasma-derived Factor XIII concentrate is used to replace the missing or deficient Factor XIII in individuals with this bleeding disorder. 

• Source: Plasma-derived Factor XIII concentrate is derived from human plasma.  
• Administration: Similar to rFXIII-A, plasma-derived Factor XIII concentrate is administered intravenously (IV) through a vein.  
• Prophylaxis and On-demand treatment: Plasma-derived Factor XIII concentrate can be used for both prophylactic (regular scheduled) treatment and on-demand treatment. Prophylactic treatment is often considered for patients with severe Factor XIII Deficiency to prevent bleeding episodes, while on-demand treatment may be used in patients with milder forms of the deficiency or when bleeding occurs. 
• Monitoring: Regular monitoring of Factor XIII levels and bleeding episodes is essential to assess the effectiveness of treatment and make necessary adjustments. 
• Safety and side effects: As with any blood product, there is a chance of risk of allergic reactions or adverse events associated with plasma-derived Factor XIII concentrate. Patients should be monitored for any signs of adverse reactions during and after infusion. 
• Infection risk: Plasma-derived products undergo rigorous screening and testing for infectious agents to minimize the risk of transmission of viruses or other pathogens. However, there is still a theoretical risk of infection transmission with any blood-derived product. 
• Individualized treatment: The treatment plan for Factor XIII Deficiency with plasma-derived Factor XIII concentrate is personalized based on the patient’s medical history, bleeding pattern, and response to therapy. 

Use of FFP (solvent/detergent [S/D] for treating Factor XIII Deficiency

Treating Factor XIII Deficiency with Fresh Frozen Plasma (FFP) that has undergone solvent/detergent (S/D) treatment is another option available.

However, it’s important to note that S/D treatment is primarily used to inactivate enveloped viruses in plasma-derived products, and it is not specifically indicated for Factor XIII Deficiency. 

• Fresh Frozen Plasma (FFP): FFP is a blood product that contains various clotting factors, including Factor XIII. It is obtained from whole blood and then frozen at very low temperatures to preserve its clotting factors. 
• Solvent/Detergent (S/D) Treatment: S/D treatment is a viral inactivation process used to reduce the risk of the viral transmission by the blood product. It involves using a solvent and detergent to inactivate enveloped viruses without affecting the biological activity of the plasma clotting factors. 
• Factor XIII Replacement: In Factor XIII Deficiency, FFP, including S/D-treated FFP, can be used to provide replacement Factor XIII to the patient. When infused, the Factor XIII in FFP can help improve clot stability and reduce bleeding episodes in individuals with this bleeding disorder. 
• Administration: S/D-treated FFP is administered through intravenous (IV) infusion. The infusion schedule and dosage are typically determined based on the patient’s individual needs and the severity of the deficiency. 
• Monitoring and Individualized Treatment: As with other Factor XIII replacement therapies, regular monitoring of Factor XIII levels and bleeding episodes is crucial to assess the effectiveness of treatment.  
• Safety and Side Effects: S/D treatment has been shown to be effective in inactivating certain enveloped viruses. However, as with any blood product, there is still a theoretical risk of transmission of infectious agents, though the risk is minimized through rigorous screening and testing procedures. 
• Other Treatment Options: Apart from S/D-treated FFP, other Factor XIII replacement therapies, such as Recombinant Factor XIII A subunit (rFXIII-A) and plasma-derived Factor XIII concentrate, are also available for the treatment of Factor XIII Deficiency. 

Use of Cryoprecipitate for treating Factor XIII Deficiency

Treating Factor XIII Deficiency with Cryoprecipitate is another option.  

• Cryoprecipitate: Cryoprecipitate is obtained by thawing Fresh Frozen Plasma (FFP) at a controlled temperature and then collecting the precipitated proteins. It contains high levels of fibrinogen, von Willebrand factor, and Factor VIII, as well as Factor XIII. 
• Factor XIII Replacement: The Factor XIII present in Cryoprecipitate can be used to replace the deficient or malfunctioning Factor XIII in patients with Factor XIII Deficiency. By administering Cryoprecipitate, the stability of blood clots can be improved, and the risk of bleeding episodes can be reduced. 
• Administration: Cryoprecipitate is typically administered through intravenous (IV) infusion. The specific dosage and infusion schedule depend on the individual condition needs and the severity of their Factor XIII Deficiency. 
• Monitoring and Individualized Treatment: Regular monitoring of Factor XIII levels and bleeding episodes is essential to assess the effectiveness of treatment with Cryoprecipitate.  
• Safety and Side Effects: As with any blood product, there is a potential risk of transfusion reactions or infectious agent transmission with Cryoprecipitate. The risk is minimized through thorough screening and testing of blood products. 
• Availability and Alternatives: Cryoprecipitate may not be as widely available as other Factor XIII replacement therapies, such as Recombinant Factor XIII A subunit (rFXIII-A) or plasma-derived Factor XIII concentrate. These alternatives offer a more purified and standardized form of Factor XIII, making them preferred options in many healthcare settings. 

Use of aminocaproic acid for treating Factor XIII Deficiency

Aminocaproic acid is a drug used to treat or prevent excessive bleeding in various medical conditions, including Factor XIII deficiency, also known as fibrin-stabilizing factor deficiency or FXIII deficiency. Factor XIII is an essential clotting factor that plays a crucial role in stabilizing blood clots by cross-linking fibrin strands. 

For individuals with Factor XIII deficiency, their blood clots are less stable and more prone to breaking down, leading to prolonged bleeding episodes. Aminocaproic acid can help address this issue by promoting clot stability and reducing bleeding.  

• Bleeding episodes: Aminocaproic acid controls and manages bleeding episodes in individuals with Factor XIII deficiency. It is especially helpful in cases where there is excessive bleeding after injury, surgery, or dental procedures. 
• Prophylaxis: Aminocaproic acid may also be used as a preventive measure to decrease risk of bleeding during surgical or dental procedures for patients with Factor XIII deficiency. It can help minimize the potential for complications associated with excessive bleeding. 
• Menorrhagia: Heavy menstrual bleeding (menorrhagia) can be a concern for women with Factor XIII deficiency. Aminocaproic acid can be used to manage and reduce excessive menstrual bleeding in these cases. 

Use of Tranexamic acid injection for treating Factor XIII Deficiency

Tranexamic acid is another medication commonly used to treat bleeding disorders, including Factor XIII deficiency. It is an antifibrinolytic agent that helps to prevent the breakdown of blood clots, thereby reducing excessive bleeding. While it is not a replacement for Factor XIII itself, it can be used as a supportive therapy to manage bleeding episodes in individuals with Factor XIII deficiency.  

• Bleeding episodes: Tranexamic acid can be administered to control and manage bleeding episodes in individuals with Factor XIII deficiency. It helps to stabilize blood clots and reduce the duration and severity of bleeding. 
• Surgical and dental procedures: Before undergoing surgical or dental procedures, individuals with Factor XIII deficiency may receive Tranexamic acid as a preventive measure to decrease risk of excessive bleeding during and after the operation. 
• Menorrhagia: Tranexamic acid can be used to manage heavy menstrual bleeding (menorrhagia) in women with Factor XIII deficiency. 

use-of-intervention-with-a-procedure-in-treating-factor-xiii-deficiency

The primary treatment intervention with a procedure for Factor XIII deficiency is the intravenous infusion of purified Factor XIII concentrates.

This procedure involves administering concentrated Factor XIII derived from human plasma or produced recombinantly directly into the patient’s bloodstream. The Factor XIII concentrates contain both the A and B subunits of the clotting factor and serve to replace the deficient or dysfunctional Factor XIII. 

• Pre-treatment Evaluation: Before the procedure, the healthcare provider will perform a thorough assessment of the individual bleeding history, Factor XIII activity levels, and any other relevant medical information. 
• Preparation: The Factor XIII concentrate is prepared according to the prescribed dose and reconstituted per the manufacturer’s instructions. 
• Intravenous Infusion: The Factor XIII concentrate is administered intravenously (IV) over time, as determined by the healthcare provider. The infusion is usually given slowly to reduce the risk of an adverse reaction. 
• Monitoring: During and after the infusion, the patient is closely monitored for signs of an adverse reaction or complications. Vital signs and coagulation parameters may be checked to ensure appropriate treatment response. 
• Post-treatment Care: After the infusion, the patient may be monitored for a short period to ensure stability and to provide any necessary post-treatment care. 

The frequency and dosage of Factor XIII concentrate infusions depend on the severity of the deficiency, the individual’s bleeding history, and the healthcare provider’s treatment plan.

In some cases, individuals with severe Factor XIII deficiency may require prophylactic treatment with regular infusions to prevent bleeding episodes. In contrast, those with milder deficiencies may receive treatment on-demand when bleeding occurs. 

Other procedures may be necessary if an individual with Factor XIII deficiency experiences significant bleeding episodes or complications.

use-of-phases-in-managing-factor-xiii-deficiency

The treatment phase of management for Factor XIII deficiency can be divided into three main phases: acute management, prophylactic treatment, and supportive care.  

• Acute Management: During acute bleeding episodes or after significant injuries or surgeries, immediate management is crucial to control bleeding and promote wound healing. Acute management typically involves the intravenous infusion of purified Factor XIII concentrates. This procedure replaces the deficient or dysfunctional Factor XIII and helps stabilize blood clots to control bleeding. The healthcare provider will determine the dosing and duration of the infusion based on the severity of the bleeding and the individual’s Factor XIII levels. Acute management aims to address active bleeding events promptly and effectively. 
• Prophylactic Treatment: Prophylactic treatment involves regular infusions of Factor XIII concentrates to prevent bleeding episodes in individuals with severe Factor XIII deficiency or a history of frequent bleeding. Prophylactic treatment is recommended for those at high risk of bleeding complications, such as individuals with severe deficiency, a history of severe bleeding episodes, or joint complications. Prophylactic treatment is designed to maintain stable Factor XIII levels in the blood, providing ongoing protection against bleeding events and promoting better overall health and well-being. 
• Supportive Care: Supportive care involves lifestyle modifications and measures to prevent injuries and minimize bleeding risks. This phase focuses on creating a safe environment for the individual and includes providing education and guidance about injury prevention, safety measures, and stress management.

Medication

Future Trends

Media Gallary

References

Factor XIII Deficiency – StatPearls – NCBI Bookshelf (nih.gov) 

Factor XIII deficiency in the Saudi population, an underestimated bleeding risk. Review article and an illustrative case report with dental complications – ScienceDirect 

Orphanet: Congenital factor XIII deficiency 

Factor XIII deficiency diagnosis: Challenges and tools – Karimi – 2018 – International Journal of Laboratory Hematology – Wiley Online Library